These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
670 related articles for article (PubMed ID: 31248921)
1. NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual health clinics in Auckland, New Zealand. Azariah S; Saxton P; Franklin R; Forster R; Werder S; Jenkins R BMJ Open; 2019 Jun; 9(6):e026363. PubMed ID: 31248921 [TBL] [Abstract][Full Text] [Related]
2. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I; BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719 [TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics of gay and bisexual men in a HIV pre-exposure prophylaxis demonstration project with equity quotas in Auckland, New Zealand. Saxton PJW; Azariah S; Franklin RA; Forster RF; Werder SF; Jenkins R; Myers JM; Rich JG; Te Wake WP; Fisher MD Sex Health; 2019 Feb; 16(1):47-55. PubMed ID: 30274568 [TBL] [Abstract][Full Text] [Related]
4. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ; JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528 [TBL] [Abstract][Full Text] [Related]
5. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP). Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439 [TBL] [Abstract][Full Text] [Related]
6. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG; Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098 [TBL] [Abstract][Full Text] [Related]
7. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial. Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE; BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918 [TBL] [Abstract][Full Text] [Related]
8. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis. Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L; Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274 [TBL] [Abstract][Full Text] [Related]
10. Feasibility and impact of online HIV/STI screening addressed to men who have sex with men and transgender women users of pre-exposure prophylaxis (PrEP) in Spain (TESTATE PrEP): a study protocol for a non-blinded randomised controlled trial. Agustí C; Martínez Riveros H; García-Pérez J; Descalzo V; Fernandez G; Ramírez-Marinero A; Gonzalez MV; Díaz Y; Montoro-Fernandez M; Romano-deGea P; Araujo SG; Muntada E; Casabona J BMJ Open; 2023 Oct; 13(10):e073459. PubMed ID: 37844988 [TBL] [Abstract][Full Text] [Related]
11. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM; Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343 [TBL] [Abstract][Full Text] [Related]
12. More than prevention: early adoption of HIV pre-exposure prophylaxis (PrEP) by gay and bisexual men in New Zealand. Punchihewa TM; Wiles J; Saxton PJW Cult Health Sex; 2024 Feb; 26(2):222-235. PubMed ID: 37067151 [TBL] [Abstract][Full Text] [Related]
13. MPrEP+ study protocol: a prospective cohort study assessing the feasibility and acceptability of an HIV pre-exposure prophylaxis (PrEP) strategy for male clients of female sex workers in Kisumu, Kenya. Mantell J; Franks J; Zerbe A; Lamb MR; Reed DM; Omollo D; Lahuerta M; Naitore D; El-Sadr WM; Agot K BMJ Open; 2022 Nov; 12(11):e064037. PubMed ID: 36332953 [TBL] [Abstract][Full Text] [Related]
14. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803 [TBL] [Abstract][Full Text] [Related]
15. Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocol. Sharma M; Chris A; Chan A; Knox DC; Wilton J; McEwen O; Mishra S; Grace D; Rogers T; Bayoumi AM; Maxwell J; Shahin R; Bogoch I; Gilbert M; Tan DHS BMC Health Serv Res; 2018 Jul; 18(1):513. PubMed ID: 29970087 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men. McManus H; Grulich AE; Amin J; Selvey C; Vickers T; Bavinton B; Zablotska I; Vaccher S; Jin F; Holden J; Price K; Yeung B; Cabrera Quichua G; Ogilvie E; McNulty A; Smith D; Guy R JAMA Netw Open; 2020 Dec; 3(12):e2030806. PubMed ID: 33355675 [TBL] [Abstract][Full Text] [Related]
17. Enumerating the population eligible for funded HIV pre-exposure prophylaxis (PrEP) in New Zealand. Saxton PJW; McAllister SM Sex Health; 2019 Feb; 16(1):63-69. PubMed ID: 30620884 [TBL] [Abstract][Full Text] [Related]
18. Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men (MSM) and transgender women (TGW) in India: Study protocol. Sahay S; Bangar S; Chandhiok N PLoS One; 2023; 18(6):e0287454. PubMed ID: 37352188 [TBL] [Abstract][Full Text] [Related]
19. Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin. Ahouada C; Diabaté S; Mondor M; Hessou S; Guédou FA; Béhanzin L; Batona G; Gning NN; Zannou DM; Alary M BMC Public Health; 2020 Aug; 20(1):1267. PubMed ID: 32819335 [TBL] [Abstract][Full Text] [Related]
20. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA; Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]